Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism.
Donnelly
R
R
Department of Medicine, Stanford University School of Medicine, California.
Morris
A D
AD
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D001581:Benzothiadiazines; D003920:Diabetes Mellitus / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004232:Diuretics; D005951:Glucose Tolerance Test / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use; D009132:Muscles / Q000187:drug effects / Q000378:metabolism; D009765:Obesity; D010084:Oxidation-Reduction; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001581:Benzothiadiazines; D004232:Diuretics; D007004:Hypoglycemic Agents; D049993:Sodium Chloride Symporter Inhibitors; D008687:Metformin